A new study suggests that newer oral weight loss drugs may do more than suppress appetite, potentially altering brain circuits that control motivation and reward, impacting how one experiences pleasure.
'The innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability.'
'The unregulated marketing has to stop. People are getting recommendations for this from gym trainers, from marriage counsellors -- that is simply unacceptable.' ''There are many ways to lose weight -- eat less, fast, exercise, eat healthy. That is how you lose weight.'
'Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five times what it was five years ago.'
'Weight loss drugs can be life changing but are not without risks,' says Dr Vishnu Radhakrishnan as he explains the truth behind Ozempic and Mounjaro.
While the introduction of branded generics is likely to accelerate volumes for GLP-1 agonists, value growth may moderate because of price erosion.
The bumper rise is due to the rising demand for the drug and patients' gradual shift towards its higher dosage.
Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.
A vehicle carrying thousands of weight loss and diabetes injections was seized in Gurugram during a raid by the Drug Control Department.
The fast-growing GLP-1 market, propelled by lower-cost generics following patent expiry, is widening availability beyond patients with obesity and diabetes -- but also driving unsupervised, appearance-led demand, according to doctors.
A 56-year-old man from Delhi has been arrested for allegedly manufacturing and selling counterfeit weight loss powder and spurious Ayurvedic products online using duplicate branding.
Inspections conducted across 49 entities including pharmacies, wholesalers, and clinics to detect violations and misleading marketing practices.
Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.
Authorities in Gurugram have uncovered a racket involving the manufacturing and sale of counterfeit Mounjaro (tirzepatide) injections, used for treating type 2 diabetes and aiding weight loss, leading to the arrest of two individuals and a nationwide alert.
'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'
Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.
The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.
Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as a global player in the fast-growing diabetes and obesity market currently dominated by the likes of Novo Nordisk and Eli Lilly.
Patients with atrial fibrillation can reverse the effects of the condition by losing weight, finds a study.
'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'
Authorities in Gurugram have uncovered a racket involving the manufacturing and sale of counterfeit Mounjaro (tirzepatide) injections, used for treating type 2 diabetes and aiding weight loss. Two individuals have been arrested, and a nationwide alert has been issued to detect the fake injections.
The 23-time Grand Slam champion, who retired from professional tennis in 2022, will headline a multi-year national marketing campaign for GLP-1 drugs, a company spokesperson said.
Authorities in Gurugram have uncovered a racket involved in the manufacturing and sale of fake Mounjaro (tirzepatide) injections, used for treating diabetes and obesity. Two people have been arrested, and a nationwide alert has been issued to trace counterfeit batches.
PCOS is being renamed PMOS. Dr Anagha Menon breaks down why the one alphabet change matters and how it affects the diagnosis of this condition for so many women.
Danish pharma major Novo Nordisk on Friday launched its blockbuster type 2 diabetes treatment injection Ozempic, globally popular for its weight-loss benefits.
At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.
A Delhi court has acquitted a health club owner of sexual harassment charges, citing vague allegations, inconsistencies in the complainant's testimony, and a flawed police investigation.
Emcure Pharmaceuticals on Monday said it saw Poviztra, its newly launched semaglutide brand, as a "long-term" opportunity in India's fast-evolving obesity and cardiometabolic therapy market, even as price competition in the glucagon-like peptide-1 (GLP-1) segment intensified.
In India, the drug is not licensed for weight loss. but as anti-diabetic medication, warns Dr Chandrakant Lahariya.
Technology Innovation: Sword or Plough looks at key moments in recent history, noting how key technological changes at pivotal moments had unimaginable consequences, both positive and negative. It makes for enjoyable and insightful reading.
While heartbreak is often seen as an emotional struggle, it is also known to cause headaches, nausea and vomiting, abdominal distress, weight gain or weight loss and could lead to a heart attack, warns Dr Rahul Bajaj.
'Any dietary approach is incomplete without physical exercise.' 'Application of calorie restriction/intermittent fasting alone would lead to a decrease in muscle mass, and possibly bone mass too.'
'We recently launched Yesintek in the immunology space.'
'What the US appears to be doing is to force India to be "the buyer of last resort", on whom their products can be dumped, 1.4 billion people have to eat something, so why not eat American corn?' 'What is exercising the Trump lot is the fact that most of the farms are in solidly Republican Midwestern states: Illinois, Indiana, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin,' points out Rajeev Srinivasan.
Here's how you can prepare yourself and your family to deal with menopause.
The $1.2 billion in-space manufacturing market is expected to grow and be worth more than $20 billion by 2033.
A recent survey revealed that 46 percent of girls and 30 percent of boys in the US, most of who are in their teens smoke to control their weight.
Tried every possible way to shed those extra pounds but unable to get results? Well, a new weight loss drug may address the problem effectively. The powerful new drug, known as tesofensine, which was originally developed as a treatment for Parkinson's and Alzheimer's disease, can help users shed nearly 12 kilos in six months. It is twice as effective as current treatments and can see overweight patients lose up to 10 per cent of their body weight quickly.
The FDA has stepped up its efforts to ensure drug safety in recent months.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances